ProCE Banner Activity

Optimal Selection of Therapy for Treatment-Naive CLL

Slideset

Download these slides from our ASH 2020 live satellite symposium on CLL to review the most current clinical data on treating patients with newly diagnosed CLL.

Released: December 03, 2020

Expiration: December 02, 2021

Share

Faculty

Jeremy S. Abramson

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmacyclics AbbVie

Janssen administered by Scientific Affairs

Lilly

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Cellectar, Foresight Diagnostics, Genentech, Gilead, Interius, Roche; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.